FDA

FDA In Brief: FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

The following quote is attributed to William Maisel, M.D., director of the Office of Product Evaluation and Quality in FDA’s Center for Devices and Radiological…

Coronavirus (COVID-19) Update: June 15, 2021

The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: Following our update on…

FDA Approves StrataGraft for the Treatment of Adults with Thermal Burns

Today, the U.S. Food and Drug Administration approved StrataGraft for the treatment of adult patients with thermal burns containing intact dermal elements (remaining deep skin…

Coronavirus (COVID-19) Update: June 11, 2021

The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On June 10, the…

FDA Takes Steps to Increase Availability of COVID-19 Vaccine

Following careful review and deliberation, the U.S. Food and Drug Administration is taking important steps that will allow a critically needed supply of the Janssen…

FDA In Brief: FDA Provides Guidance on Measuring Patient-Reported Outcomes in Cancer Clinical Trials

The following quote is attributed to Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic…

Coronavirus (COVID-19) Update: June 8, 2021

The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The White House, the…

FDA Grants Accelerated Approval for Alzheimer’s Drug

Today, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved…

FDA Approves First Treatment for Patients with Plasminogen Deficiency, a Rare Genetic Disorder

Today, the U.S. Food and Drug Administration approved Ryplazim (plasminogen, human-tvmh) for the treatment of patients with plasminogen deficiency type 1, also referred to as…

Coronavirus (COVID-19) Update: June 4, 2021

The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On June 1, the…